Nektar Therapeutics (CA) Stands to Gain $25 Million From AstraZeneca PLC Filing

Nektar Therapeutics Inc. will get $25 million from AstraZeneca plc if a European regulatory filing for an anti-constipation drug is accepted. San Francisco-based Nektar (NASDAQ: NKTR) received $125 million upfront when it inked a 2009 licensing deal with AstraZeneca for naloxegol, which is aimed at relieving constipation caused by pain-killing opioid drugs. But if the European Medicines Agency accepts AstraZeneca's application, which typically happens within 30 days, Nektar would receive the additional $25 million payout.

Help employers find you! Check out all the jobs and post your resume.